These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 30849508)

  • 1. Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease.
    Spencer B; Trinh I; Rockenstein E; Mante M; Florio J; Adame A; El-Agnaf OMA; Kim C; Masliah E; Rissman RA
    Neurobiol Dis; 2019 Jul; 127():163-177. PubMed ID: 30849508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases.
    Spencer B; Potkar R; Trejo M; Rockenstein E; Patrick C; Gindi R; Adame A; Wyss-Coray T; Masliah E
    J Neurosci; 2009 Oct; 29(43):13578-88. PubMed ID: 19864570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reducing Endogenous α-Synuclein Mitigates the Degeneration of Selective Neuronal Populations in an Alzheimer's Disease Transgenic Mouse Model.
    Spencer B; Desplats PA; Overk CR; Valera-Martin E; Rissman RA; Wu C; Mante M; Adame A; Florio J; Rockenstein E; Masliah E
    J Neurosci; 2016 Jul; 36(30):7971-84. PubMed ID: 27466341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice.
    Cooper JM; Wiklander PB; Nordin JZ; Al-Shawi R; Wood MJ; Vithlani M; Schapira AH; Simons JP; El-Andaloussi S; Alvarez-Erviti L
    Mov Disord; 2014 Oct; 29(12):1476-85. PubMed ID: 25112864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ESCRT-mediated uptake and degradation of brain-targeted α-synuclein single chain antibody attenuates neuronal degeneration in vivo.
    Spencer B; Emadi S; Desplats P; Eleuteri S; Michael S; Kosberg K; Shen J; Rockenstein E; Patrick C; Adame A; Gonzalez T; Sierks M; Masliah E
    Mol Ther; 2014 Oct; 22(10):1753-67. PubMed ID: 25008355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.
    Mandler M; Valera E; Rockenstein E; Weninger H; Patrick C; Adame A; Santic R; Meindl S; Vigl B; Smrzka O; Schneeberger A; Mattner F; Masliah E
    Acta Neuropathol; 2014; 127(6):861-79. PubMed ID: 24525765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exosome-mediated delivery of antisense oligonucleotides targeting α-synuclein ameliorates the pathology in a mouse model of Parkinson's disease.
    Yang J; Luo S; Zhang J; Yu T; Fu Z; Zheng Y; Xu X; Liu C; Fan M; Zhang Z
    Neurobiol Dis; 2021 Jan; 148():105218. PubMed ID: 33296726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation.
    Kim C; Spencer B; Rockenstein E; Yamakado H; Mante M; Adame A; Fields JA; Masliah D; Iba M; Lee HJ; Rissman RA; Lee SJ; Masliah E
    Mol Neurodegener; 2018 Aug; 13(1):43. PubMed ID: 30092810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity.
    Price DL; Rockenstein E; Ubhi K; Phung V; MacLean-Lewis N; Askay D; Cartier A; Spencer B; Patrick C; Desplats P; Ellisman MH; Masliah E
    PLoS One; 2010 Nov; 5(11):e14020. PubMed ID: 21103359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel systemic delivery of a peptide-conjugated antisense oligonucleotide to reduce α-synuclein in a mouse model of Alzheimer's disease.
    Leitão ADG; Ahammad RU; Spencer B; Wu C; Masliah E; Rissman RA
    Neurobiol Dis; 2023 Oct; 186():106285. PubMed ID: 37690676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson's Disease/Dementia with Lewy Bodies.
    Price DL; Rockenstein E; Mante M; Adame A; Overk C; Spencer B; Duong-Polk KX; Bonhaus D; Lindsey J; Masliah E
    Sci Rep; 2016 Jul; 6():29523. PubMed ID: 27389831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy.
    Spencer B; Valera E; Rockenstein E; Overk C; Mante M; Adame A; Zago W; Seubert P; Barbour R; Schenk D; Games D; Rissman RA; Masliah E
    Acta Neuropathol Commun; 2017 Jan; 5(1):7. PubMed ID: 28086964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy.
    Crews L; Spencer B; Desplats P; Patrick C; Paulino A; Rockenstein E; Hansen L; Adame A; Galasko D; Masliah E
    PLoS One; 2010 Feb; 5(2):e9313. PubMed ID: 20174468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneity in α-synuclein subtypes and their expression in cortical brain tissue lysates from Lewy body diseases and Alzheimer's disease.
    Vaikath NN; Erskine D; Morris CM; Majbour NK; Vekrellis K; Li JY; El-Agnaf OMA
    Neuropathol Appl Neurobiol; 2019 Oct; 45(6):597-608. PubMed ID: 30422353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accumulation of alpha-synuclein within the liver, potential role in the clearance of brain pathology associated with Parkinson's disease.
    Reyes JF; Ekmark-Léwen S; Perdiki M; Klingstedt T; Hoffmann A; Wiechec E; Nilsson P; Nilsson KPR; Alafuzoff I; Ingelsson M; Hallbeck M
    Acta Neuropathol Commun; 2021 Mar; 9(1):46. PubMed ID: 33743820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?
    Fujita M; Sekigawa A; Sekiyama K; Sugama S; Hashimoto M
    J Neurol; 2009 Aug; 256 Suppl 3():286-92. PubMed ID: 19711118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5--implications for dementia with Lewy bodies.
    Overk CR; Cartier A; Shaked G; Rockenstein E; Ubhi K; Spencer B; Price DL; Patrick C; Desplats P; Masliah E
    Mol Neurodegener; 2014 May; 9():18. PubMed ID: 24885390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-invasive systemic viral delivery of human alpha-synuclein mimics selective and progressive neuropathology of Parkinson's disease in rodent brains.
    Bérard M; Martínez-Drudis L; Sheta R; El-Agnaf OMA; Oueslati A
    Mol Neurodegener; 2023 Nov; 18(1):91. PubMed ID: 38012703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
    Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease.
    Masliah E; Rockenstein E; Mante M; Crews L; Spencer B; Adame A; Patrick C; Trejo M; Ubhi K; Rohn TT; Mueller-Steiner S; Seubert P; Barbour R; McConlogue L; Buttini M; Games D; Schenk D
    PLoS One; 2011 Apr; 6(4):e19338. PubMed ID: 21559417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.